FOUNDATIONONE®LIQUID CDx

PATIENT
Lai, Mei-Ying

TUMOR TYPE
Lung adenocarcinoma
COUNTRY CODE
TW

REPORT DATE
19 Jul 2022
ORDERED TEST #
ORD-1409301-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT
DISEASE Lung adenocarcinoma
NAME Lai, Mei-Ying
DATE OF BIRTH 15 December 1940
SEX Female
MEDICAL RECORD # 44841205

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN ID MYL 12/15/1940
SPECIMEN TYPE Blood
DATE OF COLLECTION 07 July 2022
SPECIMEN RECEIVED 11 July 2022

Biomarker Findings

Blood Tumor Mutational Burden - 4 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction Not Detected

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

MET **exon 14 splice site (2888-21_2888-11del11)**
DNMT3A **Y533C**
KEL **R428C**

Report Highlights

- Targeted therapies with **NCCN categories of evidence** in this tumor type: **Capmatinib** (p. 8), **Crizotinib** (p. 8), **Tepotinib** (p. 9)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 11)
- Variants that may represent **clonal hematopoiesis** and may originate from non-tumor sources: ***DNMT3A*** **Y533C** (p. 7)

BIOMARKER FINDINGS

Blood Tumor Mutational Burden
- 4 Muts/Mb

Microsatellite status
- MSI-High Not Detected

Tumor Fraction
- Elevated Tumor Fraction Not Detected

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).

Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. The fact that elevated tumor fraction was not detected in this specimen indicates the possibility of lower levels of ctDNA but does not compromise confidence in any reported alterations. However, in the setting of a negative liquid biopsy result, orthogonal testing of a tissue specimen should be considered if clinically indicated (see Biomarker Findings section).

GENOMIC FINDINGS	VAF %
MET - exon 14 splice site (2888-21_2888-11del11)	0.79%

10 Trials see p. 11

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)		THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
Capmatinib	2A	Cabozantinib
Crizotinib	2A	
Tepotinib	2A	

☐ *NCCN category*

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

DNMT3A - Y533C ..... p. 7

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

DNMT3A - Y533C ..... p. 7

KEL - R428C ..... p. 7

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531



HISTORIC PATIENT FINDINGS		ORD-1409301-01 VAF%
Blood Tumor Mutational Burden		4 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Elevated Tumor Fraction Not Detected
MET	● exon 14 splice site (2888-21_2888-11del11)	0.79%
DNMT3A	● Y533C	1.5%
KEL	● R428C	50.8%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT
4 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-3], anti-PD-1[3-4], and anti-PD-1/CTLA4 therapies[5-6] . A Phase 2 multi-solid-tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor[5]. In non-small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single-agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb-16 Muts/Mb[1]. In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[7].

FREQUENCY & PROGNOSIS

NSCLC harbors a median bTMB of 16.8 Muts/Mb (range 1.9-52.5 Muts/Mb)[4]. Retrospective analysis of the Phase 3 OAK and Phase 2 POPLAR trials for patients with advanced or metastatic non-small cell lung cancer (NSCLC) reported that bTMB ≥7 Muts/Mb was associated with shorter PFS (2.8 vs. 4.2 months) and OS (7.4 vs. 11.9 months) compared with bTMB <7 Muts/Mb for patients treated with docetaxel[8]. In one study of advanced NSCLC in China, bTMB ≥6 Muts/Mb was associated with decreased PFS (10 vs. 18 months) and OS (11 vs. 25 months) compared with bTMB <6 Muts/Mb for patients treated with platinum-based chemotherapy[9]. A meta-analysis of 19 studies of immune checkpoint inhibitor-treated NSCLC (n = 2,315 patients) demonstrated that high TMB predicted a significantly longer OS than low TMB (HR = 0.70), and within the high TMB group, immunotherapy was associated with an improved PFS (HR = 0.62, P<0.001), OS (HR = 0.67, P<0.001) and a higher response rate (OR = 2.35, P<0.001) compared to chemotherapy[10]. In contrast, a large study of Chinese patients with untreated lung adenocarcinoma reported a shorter median OS for tumors with a higher number of mutations in a limited gene set compared with a lower mutation number (48.4 vs. 61.0 months)[11]. Another study of patients with NSCLC treated with EGFR inhibitors or platinum doublet chemotherapy found elevated TMB to be correlated with poorer prognosis, as well as finding lower TMB in combination with PD-L1 negative status to be significantly associated with longer median survival in patients with lung adenocarcinoma[12]. However, no significant prognostic association of TMB and/or PD-L1 status with survival has been reported in patients with lung SCC[12-13].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[14-15] and cigarette smoke in lung cancer[16-17], treatment with temozolomide-based chemotherapy in glioma[18-19], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[20-24], and microsatellite instability (MSI)[20,23-24]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-2,4]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Tumor Fraction

RESULT

Elevated Tumor Fraction Not Detected

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[25-30].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[31]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[32], Ewing sarcoma and osteosarcoma[33], prostate cancer[28], breast cancer[34], leiomyosarcoma[35], esophageal cancer[36], colorectal cancer[37], and gastrointestinal cancer[38].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[39], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[40-41].

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE

MET

ALTERATION
exon 14 splice site (2888-21_2888-11del11)

TRANSCRIPT ID
NM_000245

CODING SEQUENCE EFFECT
2888-21_2888-11del11

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of extensive clinical evidence, MET amplification or activating mutations may predict sensitivity to MET-targeting therapies such as kinase inhibitors crizotinib, capmatinib, tepotinib, and cabozantinib. MET inhibitors crizotinib, capmatinib, PF-04217903, tepotinib, glesatinib, savolitinib, and foretinib have provided benefit for patients with MET-mutated papillary renal cell carcinoma (RCC)[42-45], histiocytic sarcoma[46], and non-small cell lung cancer (NSCLC) of varied histologies[47-51]. Patients with MET exon 14 mutated NSCLC who were treated with 1 of several MET inhibitors exhibited superior outcomes (median OS 24.6 vs. 8.1 months; HR=0.11, p=0.04) compared with patients who were not treated with a MET inhibitor[52]. Tepotinib showed durable clinical activity in patients with NSCLC with MET exon 14 skipping mutations[53], and yielded a PR lasting 9 months for a patient with HLA-DRB1-MET fusion-positive NSCLC[54]. In another study, 11 patients with hereditary papillary RCC and germline MET mutations (4 of which were H1094R) experienced 5 PRs and 5 SDs after treatment with foretinib[42]. Savolitinib yielded ORRs of 49% (30/61) in patients with MET exon 14 mutated NSCLC[55] and numerically higher ORR for patients with MET-driven papillary RCC compared to sunitinib (27% [9/33] vs. 7.4% [2/27])[45]. A Phase 1 study for patients with MET-altered NSCLC treated with MET inhibitor bozitinib monotherapy reported an overall ORR of 30.6% (11/36) and DCR of 97.2% (35/36) with MET overexpression, amplification, and exon 14 skipping demonstrating ORRs of 35.7% (5/14), 41.2% (7/17), and 66.7% (10/15), respectively; increased ORRs were observed in patients with both exon 14 skipping and amplification (100%, 4/4) and with both amplification and overexpression (50%, 3/6)[56]. A Phase 2 study evaluating the MET inhibitor savolitinib for patients with MET exon 14 splice site mutation-positive pulmonary sarcomatoid carcinoma and other types of non-small cell lung cancer (NSCLC) reported that 52% (16/31) of patients achieved a PR[57]. In the Phase 1 CHRYSALIS study, patients with NSCLC harboring MET exon 14 skipping mutations treated with amivantamab achieved a 64% (9/14; 5 PRs confirmed, 4 PRs pending) unconfirmed ORR; 4 out of 7 patients previously treated with MET TKIs responded (Spira et al., 2021 WCLC Abstract OA15.03).

FREQUENCY & PROGNOSIS

In the Phase 2 VISION study of patients with non-small cell lung cancer, MET exon 14 skipping alterations were reported in 3.6% of patients[58]. In one study of 4402 lung adenocarcinoma cases, MET mutations (primarily those affecting MET exon 14 splicing) have been reported in 3% of samples[46]. In TCGA datasets, MET mutation has been observed in 8.3% of lung adenocarcinomas and 2.1% of lung squamous cell carcinomas[59-60]. Studies on the effect of MET amplification on prognosis in NSCLC have yielded conflicting results[61-68], although concurrent MET amplification and EGFR mutation have been correlated with reduced disease-free survival[69]. MET exon 14 splice alteration, which has predominantly been observed in lung cancer, was found to be an independent poor prognostic factor in a study of 687 patients with NSCLC[70]. However, other studies did not find MET exon 14 splice alteration as a major risk factor for overall survival for NSCLC patients, although recurrence rate was significantly higher in patients with exon 14 splice alteration compared to those with ALK fusion[71-72]. Among NSCLC patients with exon 14 alterations that had not been previously treated with a MET inhibitor, a non-significant trend for reduced survival was noted in the context of concurrent MET amplification (5.2 vs 10.5 months, p = 0.06)[52].

FINDING SUMMARY

MET encodes a receptor tyrosine kinase, also known as c-MET or hepatocyte growth factor receptor (HGFR), that is activated by the ligand HGF; MET activation results in signaling mediated partly by the RAS-RAF-MAPK and PI3K pathways to promote proliferation[73-74]. Certain MET alterations have been associated with the removal of exon 14[48,75-79] and/or loss of a binding site for the ubiquitin ligase CBL, an enzyme that targets MET for degradation[75,80-82]. Loss of either MET exon 14 or a CBL binding site increases MET stability, leading to prolonged signaling upon HGF stimulation and increased oncogenic potential[75,79,81-85]; these mutations are expected to be activating. Responses to various MET inhibitors have been reported for multiple patients with alterations in their tumors predicted to lack MET exon 14[46,48,86-90].

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
DNMT3A

ALTERATION
Y533C

TRANSCRIPT ID
NM_022552

CODING SEQUENCE EFFECT
1598A>G

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors.

FREQUENCY & PROGNOSIS

DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)[91-92]. Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022).

FINDING SUMMARY

The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation[93-94]. The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor[95-100]. Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

POTENTIAL CLONAL HEMATOPOIESIS

IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[101-106]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[101-102]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[107]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[105,108-109]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

GENE
KEL

ALTERATION
R428C

TRANSCRIPT ID
NM_000420

CODING SEQUENCE EFFECT
1282C>T

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies available to target genomic alterations in KEL.

FREQUENCY & PROGNOSIS

KEL mutations have been reported up to 3.0% in tumors of the lung, endometrium, stomach, large intestine, soft tissue, and liver, with a higher incidence of 8.0% in various skin tumors (COSMIC, 2022)[110]. However, the mechanism by which KEL mutations may contribute to tumorigenesis is not known.

FINDING SUMMARY

KEL encodes a transmembrane glycoprotein with similarities to zinc-dependent metalloproteases; this glycoprotein is highly polymorphic and forms the Kell blood group antigen[111].

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Capmatinib

Assay findings association

MET
exon 14 splice site
(2888-21_2888-11del11)

AREAS OF THERAPEUTIC USE

Capmatinib is a selective MET tyrosine kinase inhibitor that is FDA approved to treat patients with non-small cell lung cancer harboring MET exon 14 skipping-associated alterations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Based on extensive clinical data in NSCLC[53,55,112-115] , MET mutations associated with exon 14 skipping may predict sensitivity to selective MET inhibitors.

SUPPORTING DATA

Capmatinib monotherapy has demonstrated clinical activity for patients with advanced NSCLC harboring MET exon 14 skipping alterations and lacking EGFR mutations or ALK rearrangements[116-117] . The Phase 2 GEOMETRY mono-1 study reported a higher ORR (67.9% vs. 40.6%) and DCR (96.4% vs. 78.3%), and longer PFS (12.4 vs. 5.4 months) and median duration of response (12.6 vs. 9.7 months) for treatment-naive patients with exon 14 mutations when compared with those who were previously treated; no correlation was observed between patient responses and the presence of co-occurring MET amplification[112]. Additionally, this study recorded a 53.8% (7/13) intracranial response rate and 92.3% (12/13) intracranial DCR[116]. A retrospective analysis of the GEOMETRY mono-1 study compared with a cohort of real-world (RW) patients with NSCLC harboring MET exon 14 skipping alterations who received first-line chemotherapy and/or immunotherapy reported a longer PFS (mPFS 12.0 vs mrwPFS 6.2 months) for patients that received capmatinib compared to chemotherapy and/or immunotherapy used in the real-world[118]. Multiple Phase 1 and 2 clinical studies have reported limited efficacy for capmatinib monotherapy in non-NSCLC indications, with no responses observed for patients with glioblastoma (n=10)[119], gastric cancer (n=9), or other advanced solid tumors (n=24)[120-121] .

Crizotinib

Assay findings association

MET
exon 14 splice site
(2888-21_2888-11del11)

AREAS OF THERAPEUTIC USE

Crizotinib is an inhibitor of the kinases MET, ALK, ROS1, and RON. It is FDA approved to treat patients with ALK rearrangement- or ROS1 rearrangement-positive non-small cell lung cancer (NSCLC), adult and pediatric patients with ALK-positive inflammatory myofibroblastic tumor (IMT), and pediatric and young adult patients with ALK-positive anaplastic large cell lymphoma (ALCL). Please see the drug label for full prescribing information.

GENE ASSOCIATION

Sensitivity of MET alterations to crizotinib is suggested by extensive clinical data in patients with MET-amplified cancers, including non-small cell lung cancer (NSCLC)[122-126] , gastric cancer[127], gastroesophageal cancer[128], glioblastoma[129], and carcinoma of unknown primary[130], as well as in patients with MET-mutated cancers, including NSCLC[46,48-51,131] , renal cell carcinoma (RCC)[44], and histiocytic sarcoma[46]. Crizotinib has also benefited patients with NSCLC or histiocytic sarcoma tumors harboring various alterations associated with MET exon 14 skipping[46,48-52] .

SUPPORTING DATA

The expansion cohort of the PROFILE 1001 study reported a 32.3% (21/65, 3 CRs) ORR, 7.3 month median PFS, and 20.5 month median OS for patients with advanced MET exon 14-altered NSCLC[132]. Other Phase 2 studies have reported ORRs of 20.0% to 35.7%, median PFS of 2.4 to 2.6 months, and median OS of 3.8 to 8.1 months for patients with MET-mutated NSCLC[133-134] . A retrospective study reported median PFS of 7.4 months in patients with MET exon 14-altered NSCLC treated with crizotinib[135]. In a small study for patients with NSCLC and MET overexpression with or without gene amplification, crizotinib elicited 11 PRs and 3 SDs in 19 evaluable patients[123]. Crizotinib has demonstrated efficacy in patients with NSCLC and ALK rearrangements[136-140] , ROS1 rearrangements[134,141-144] , an NTRK1 fusion[145], or MET activation[48-51,78,122-126,131,146-151] .

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Tepotinib

Assay findings association

MET
exon 14 splice site
(2888-21_2888-11del11)

AREAS OF THERAPEUTIC USE

Tepotinib is a selective MET tyrosine kinase inhibitor that is FDA approved to treat patients with non-small cell lung cancer harboring MET exon 14 skipping alterations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Based on extensive clinical data in NSCLC[53,55,112-115] , MET mutations associated with exon 14 skipping may predict sensitivity to selective MET inhibitors.

SUPPORTING DATA

In the Phase 2 VISION study, tepotinib yielded an ORR of 45%, median duration of response (DOR) of 11 months, and median PFS of 8.9 months for patients with NSCLC and MET exon 14 skipping alterations, with similar ORRs observed for treatment-naïve and previously treated patients[53,115] . Among patients with brain metastases, tepotinib yielded an ORR of 57% (8/14)[152], median DOR of 9.5 months, and median PFS of 10.9 months[53]. Tepotinib has primarily been investigated in non-small cell lung cancer (NSCLC) and has demonstrated efficacy as a single agent for patients with MET amplification[153] and MET exon 14-skipping alterations[53,115] . Tepotinib has also been shown to be efficacious in combination with gefitinib for patients with concurrent EGFR mutation and MET amplification or MET overexpression in Phase 2 studies[154-155] . A case study reported 1 PR lasting 9 months for a patient with HLA-DRB1-MET fusion-positive NSCLC metastatic to the brain[54].

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Cabozantinib

Assay findings association

MET
exon 14 splice site
(2888-21_2888-11del11)

AREAS OF THERAPEUTIC USE

Cabozantinib inhibits multiple tyrosine kinases, including MET, RET, VEGFRs, and ROS1. It is FDA approved as monotherapy to treat patients with renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer (MTC), and differentiated thyroid cancer (DTC). It is also approved in combination with nivolumab to treat RCC. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Sensitivity of MET alterations to cabozantinib is suggested by clinical responses in patients with non-small cell lung cancer (NSCLC) harboring MET mutations associated with MET exon 14 skipping, with or without concurrent MET amplification[48,156] , as well as by extensive preclinical data[157-163] .

SUPPORTING DATA

Cabozantinib elicited a CR in a patient with lung adenocarcinoma harboring a MET amplification and a mutation affecting MET exon 14 splicing[48]. A Phase 2 randomized discontinuation trial of cabozantinib reported a 10.0% (6/60) ORR and a 58.3% (35/60) DCR, with median PFS of 4.2 months, for patients with genomically unselected, heavily pretreated NSCLC[164]. Patients with EGFR wild-type non-squamous NSCLC who had progressed after previous treatment experienced longer median PFS with cabozantinib alone or combined with erlotinib (4.3 and 4.7 months, HR=0.39 and 0.37, respectively) compared with single agent erlotinib (1.8 months) in a randomized Phase 2 trial[165]. A Phase 1 study of cabozantinib for advanced solid tumors reported an ORR of 20.0% (4/20; 4 PRs, all in EGFR-mutated tumors) and DCR of 100% (20/20) in the expansion cohort for Japanese patients with NSCLC[166].

NOTE Genomic alterations detected may be associated with activity of certain US FDA or other specific country approved therapies; however, the therapies listed in this report may have varied evidence in the patient's tumor type. The listed therapies are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. The therapies listed in this report may not be complete and/or exhaustive. Furthermore, the listed therapies are limited to US FDA approved pharmaceutical drug products that are linked to a specific genomic alteration. There may also be US FDA approved pharmaceutical drug products that are not linked to a genomic alteration. Further there may also exist pharmaceutical drug products that are not approved by the US FDA or other national authorities. There may also be other treatment modalities available than pharmaceutical drug products.

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
MET

ALTERATION
exon 14 splice site
(2888-21_2888-11del11)

RATIONALE
Activating MET alterations may confer sensitivity to MET inhibitors.

NCT03539536

PHASE 2

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

TARGETS
MET

LOCATIONS: Taipei (Taiwan), New Taipei City (Taiwan), Taoyuan City (Taiwan), Taipei City (Taiwan), Taichung (Taiwan), Chia-Yi (Taiwan), Fuzhou (China), Tainan (Taiwan), Kaohsiung (Taiwan), Hangzhou (China)

NCT03175224

PHASE 1/2

CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation

TARGETS
MET

LOCATIONS: Taipei City (Taiwan), Taipei (Taiwan), New Taipei City (Taiwan), Taoyuan City (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Singapore (Singapore), Nedlands (Australia), North Adelaide (Australia), Bedford Park (Australia)

NCT02099058

PHASE 1

A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors

TARGETS
MET, EGFR, PD-1

LOCATIONS: Taipei City (Taiwan), Tainan (Taiwan), Suwon (Korea, Republic of), Seoul (Korea, Republic of), Chuo-ku (Japan), Kashiwa-shi (Japan), Marseille CEDEX 05 (France), California, Colorado

NCT04677595

PHASE 2

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

TARGETS
MET

LOCATIONS: Xiamen (China), Hangzhou (China), Shanghai (China), Guangzhou (China), Foshan (China), Changsha (China), Wuhan (China), Zhanjing (China), Zhengzhou (China), Jinan (China)

NCT04923945

PHASE 3

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

TARGETS
MET

LOCATIONS: Shanghai (China)

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT05009836

PHASE 3

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

TARGETS MET, EGFR

LOCATIONS: Guangzhou (China)

NCT04077099

PHASE 1/2

REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

TARGETS MET

LOCATIONS: Suwon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi do (Korea, Republic of), Dijon Cedex (France), Grenoble (France), Caen cedex (France), Rennes Cedex 9 (France), California, Pennsylvania, Texas

NCT04427072

PHASE 3

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

TARGETS MET

LOCATIONS: Seoul (Korea, Republic of), Gyeonggi do (Korea, Republic of), Hanoi (Vietnam), Bangkok (Thailand), Songkhla (Thailand), Kuantan (Malaysia), Pulau Pinang (Malaysia), Kuala Lumpur (Malaysia), New Delhi (India), Vellore (India)

NCT04258033

PHASE 2

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation

TARGETS MET

LOCATIONS: Guangzhou (China)

NCT04647838

PHASE 2

Tepotinib in Solid Tumors Harboring MET Alterations

TARGETS MET

LOCATIONS: Cheonan (Korea, Republic of), Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of)

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

APC A2800V	***BRCA2*** Q3036E	***C11ORF30 (EMSY)*** V739A	***NTRK1*** E275A
PMS2 V200I	***RB1*** S350N	***RICTOR*** N12K	***SNCAIP*** E498K

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B or WTX)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	***CCND1***	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*	***CD274*** **(PD-L1)**	*CDC73*
CDH1	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*	***CDKN2A***	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2 **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15**, 24-27**	*EMSY* (C11orf30)	*EP300*	*EPHA3*
EPHB1	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***	***ESR1*** **Exons 4-8**
*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FANCA*	*FANCC*	*FANCG*
FANCL	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*	*FGF23*	*FGF3*
FGF4	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*	*FLCN*	*FLT1*
FLT3 **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*	*GID4* (C17orf39)	***GNA11*** **Exons 4, 5**
GNA13	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3-3A* (H3F3A)	*HDAC1*	*HGF*	*HNF1A*
HRAS **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*	*INPP4B*
IRF2	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*	*KDM5C*
KDM6A	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)	

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

KRAS	*LTK*	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*
MAPK1	*MCL1*	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***
MITF	*MKNK1*	*MLH1*	***MPL*** **Exon 10**	*MRE11* (MRE11A)	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*
MTAP	***MTOR*** **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*
NF1	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**
NRAS **Exons 2, 3**	*NSD2* (WHSC1 or MMSET)	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*
PALB2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**
PDGFRB **Exons 12-21, 23**	*PDK1*	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PRKN* (PARK2)
PTCH1	***PTEN***	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*
RAD51C	*RAD51D*	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*
RET Introns 7, 8, **Exons 11, 13-16, Introns 9-11**	*RICTOR*	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*
SDHC	*SDHD*	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*
SMARCB1	***SMO***	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*
STAG2	*STAT3*	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C* (FAM46C)	*TERC** ncRNA
TERT* **Promoter**	*TET2*	*TGFBR2*	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*
TSC2	*TYRO3*	*U2AF1*	***VEGFA***	*VHL*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*
ZNF703								

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status
Blood Tumor Mutational Burden (bTMB)
Tumor Fraction

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version 6.3.0

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Sturgill EG, et al. Oncologist (2022) pmid: 35274716
4. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
5. Schenker et al., 2022; AACR Abstract CT022
6. Saori et al., 2021; ESMO Abstract 80P
7. Li et al., 2020; ASCO Abstract 6511
8. Nie W, et al. J Natl Compr Canc Netw (2020) pmid: 32380463
9. Ma Y, et al. Front Oncol (2021) pmid: 34055609
10. Meng G, et al. PLoS One (2022) pmid: 35113949
11. Xiao D, et al. Oncotarget (2016) pmid: 27009843
12. Chen Y, et al. J. Exp. Clin. Cancer Res. (2019) pmid: 31088500
13. Yu H, et al. J Thorac Oncol (2019) pmid: 30253973
14. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
15. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
16. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
17. Rizvi NA, et al. Science (2015) pmid: 25765070
18. Johnson BE, et al. Science (2014) pmid: 24336570
19. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
20. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
21. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
22. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
23. Nature (2012) pmid: 22810696
24. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
25. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
26. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
27. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
28. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
29. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
30. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
31. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
32. Lapin M, et al. J Transl Med (2018) pmid: 30400802
33. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
34. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
35. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
36. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
37. Fan G, et al. PLoS ONE (2017) pmid: 28187169
38. Vu et al., 2020; DOI: 10.1200/PO.19.00204
39. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
40. Zhang EW, et al. Cancer (2020) pmid: 32757294
41. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
42. Choueiri TK, et al. J. Clin. Oncol. (2013) pmid: 23213094
43. Diamond JR, et al. J. Clin. Oncol. (2013) pmid: 23610116
44. Stein MN, et al. Eur. Urol. (2015) pmid: 25457019
45. Choueiri TK, et al. JAMA Oncol (2020) pmid: 32469384
46. Frampton GM, et al. Cancer Discov (2015) pmid: 25971938
47. Engstrom LD, et al. Clin. Cancer Res. (2017) pmid: 28765324
48. Paik PK, et al. Cancer Discov (2015) pmid: 25971939
49. Jenkins RW, et al. Clin Lung Cancer (2015) pmid: 25769807
50. Waqar SN, et al. J Thorac Oncol (2015) pmid: 25898962
51. Mendenhall MA, et al. J Thorac Oncol (2015) pmid: 25898965
52. Awad et al., 2017; ASCO Abstract 8511
53. Paik PK, et al. N. Engl. J. Med. (2020) pmid: 32469185
54. Blanc-Durand F, et al. Oncologist (2020) pmid: 32716573
55. Lu et al., 2020; ASCO Abstract 9519
56. Yang et al., 2020; AACR Abstract CT127
57. Lu et al., 2019; AACR Abstract CT031
58. Le et al., 2020; AACR Abstract 3385
59. Nature (2014) pmid: 25079552
60. Nature (2012) pmid: 22960745
61. Yang JJ, et al. Lung Cancer (2013) pmid: 23079155
62. Dziadziuszko R, et al. J Thorac Oncol (2012) pmid: 22237262
63. Cappuzzo F, et al. J. Clin. Oncol. (2009) pmid: 19255323
64. Park S, et al. Histol. Histopathol. (2012) pmid: 22207554
65. Chen YT, et al. J Thorac Oncol (2011) pmid: 22052229
66. Kanteti R, et al. J. Environ. Pathol. Toxicol. Oncol. (2009) pmid: 19817696
67. To C, et al. Exp. Cell Res. (2002) pmid: 11795945
68. Tsuta K, et al. J Thorac Oncol (2012) pmid: 22198430
69. Tanaka A, et al. Lung Cancer (2012) pmid: 21733594
70. Tong JH, et al. Clin. Cancer Res. (2016) pmid: 26847053
71. Lee GD, et al. J Thorac Oncol (2017) pmid: 28502721
72. Gow CH, et al. Lung Cancer (2017) pmid: 28024701
73. J. Clin. Oncol. (2011) pmid: 22042966
74. Jung KH, et al. Arch. Pharm. Res. (2012) pmid: 22553051
75. Kong-Beltran M, et al. Cancer Res. (2006) pmid: 16397241
76. Onozato R, et al. J Thorac Oncol (2009) pmid: 19096300
77. Okuda K, et al. Cancer Sci. (2008) pmid: 19037978
78. Awad MM, et al. J. Clin. Oncol. (2016) pmid: 26729443
79. Gray MJ, et al. Am. J. Hum. Genet. (2015) pmid: 26637977
80. Peschard P, et al. J. Biol. Chem. (2004) pmid: 15123609
81. Lee JM, et al. Oncogene (2014) pmid: 23208509
82. Lee JH, et al. Exp. Mol. Med. (2006) pmid: 17079873
83. Togashi Y, et al. Lung Cancer (2015) pmid: 26547802
84. Peschard P, et al. Mol. Cell (2001) pmid: 11741535
85. Abella JV, et al. Mol. Cell. Biol. (2005) pmid: 16227611
86. Drilon et al., 2018; WCLC Abstract OA12.02
87. Felip et al., 2018; WCLC Abstract OA12.01
88. Wolf et al., 2018; ESMO Abstract LBA52
89. Moro-Sibilot et al., 2018; WCLC Abstract OA12.03
90. Berry ZS, et al. JAMA (1993) pmid: 8315738
91. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
92. Gao J, et al. Sci Signal (2013) pmid: 23550210
93. Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773
94. Prog Mol Biol Transl Sci (2011) pmid: 21507354
95. Yang J, et al. Mol Med Rep () pmid: 21887466
96. Vallböhmer D, et al. Clin Lung Cancer (2006) pmid: 16870044
97. Daskalos A, et al. Cancer (2011) pmid: 21351083
98. Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317
99. Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581
100. Kim MS, et al. APMIS (2013) pmid: 23031157
101. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
102. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
103. Xie M, et al. Nat. Med. (2014) pmid: 25326804
104. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
105. Severson EA, et al. Blood (2018) pmid: 29678827
106. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
107. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
108. Chabon JJ, et al. Nature (2020) pmid: 32269342
109. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
110. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
111. Clapéron A, et al. J. Biol. Chem. (2005) pmid: 15769748
112. Wolf et al., 2019; ASCO Abstract 9004
113. Schuler et al., 2016; ASCO Abstract 9067
114. Riedel et al., 2019; ASCO abstract 9030
115. Mazieres et al., 2020; ESMO Abstract 1283P
116. Wolf J, et al. N Engl J Med (2020) pmid: 32877583
117. Schuler M, et al. Ann. Oncol. (2020) pmid: 32240796
118. Wolf et al., 2020; ESMO Abstract 1346P
119. van den Bent M, et al. J. Neurooncol. (2020) pmid: 31776899
120. Bang YJ, et al. Cancer Sci. (2020) pmid: 31778267
121. Esaki T, et al. Cancer Sci. (2019) pmid: 30724423
122. Vassal et al., 2015; ASCO Abstract 2595
123. Li et al., 2015; ASCO Abstract 8090
124. Ou SH, et al. J Thorac Oncol (2011) pmid: 21623265
125. Schwab R, et al. Lung Cancer (2014) pmid: 24192513
126. Le X, et al. Clin Lung Cancer (2015) pmid: 25922291
127. Ali SM, et al. Oncologist (2015) pmid: 25882375
128. Lennerz JK, et al. J. Clin. Oncol. (2011) pmid: 22042947
129. Chi AS, et al. J. Clin. Oncol. (2012) pmid: 22162573
130. Palma NA, et al. Case Rep Oncol (2014) pmid: 25232318
131. Benderra MA, et al. J Thorac Oncol (2016) pmid: 26845121
132. Drilon A, et al. Nat. Med. (2020) pmid: 31932802
133. Landi L, et al. Clin. Cancer Res. (2019) pmid: 31416808
134. Moro-Sibilot D, et al. Ann. Oncol. (2019) pmid: 31584608
135. Awad MM, et al. Lung Cancer (2019) pmid: 31200835
136. Shaw et al., 2016; ASCO Abstract 9066
137. Lu et al., 2016; ASCO Abstract 9058
138. Yoshida T, et al. J. Clin. Oncol. (2016) pmid: 27354483
139. Solomon BJ, et al. N. Engl. J. Med. (2014) pmid: 25470694
140. Shaw AT, et al. N. Engl. J. Med. (2013) pmid: 23724913
141. Goto et al., 2016; ASCO Abstract 9022
142. Shaw AT, et al. N. Engl. J. Med. (2014) pmid: 25264305
143. Mazières J, et al. J. Clin. Oncol. (2015) pmid: 25667280
144. Scheffler M, et al. Oncotarget (2015) pmid: 25868855
145. Vaishnavi A, et al. Nat. Med. (2013) pmid: 24162815
146. Drilon et al., 2016; ASCO Abstract 108
147. Camidge et al., 2014; ASCO Abstract 8001
148. Schrock AB, et al. J Thorac Oncol (2016) pmid: 27343443
149. Jorge SE, et al. Lung Cancer (2015) pmid: 26791794
150. Mahjoubi L, et al. Invest New Drugs (2016) pmid: 26892698
151. Zhang Y, et al. J Thorac Oncol (2016) pmid: 26724472
152. Viteri et al., 2020; ESMO Abstract 1286P
153. Le et al., 2021; ASCO Abstract 9021
154. Wu et al., 2019; IASLC Abstract MA09.09
155. Park et al., 2019; ESMO Abstract 477O
156. Klempner SJ, et al. J Thorac Oncol (2017) pmid: 27693535
157. Yakes FM, et al. Mol. Cancer Ther. (2011) pmid: 21926191
158. Weber H, et al. J Biomol Screen (2014) pmid: 25260782
159. Navis AC, et al. PLoS ONE (2013) pmid: 23484006
160. Yeh I, et al. Nat Commun (2015) pmid: 26013381
161. Lee YH, et al. Cancers (Basel) (2014) pmid: 25534569
162. Torres KE, et al. Clin. Cancer Res. (2011) pmid: 21540237

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

163. Sameni M, et al. Clin. Cancer Res. (2016) pmid: 26432786

164. Hellerstedt BA, et al. Clin Lung Cancer (2019) pmid: 30528315

165. Neal JW, et al. Lancet Oncol. (2016) pmid: 27825638

166. Nokihara H, et al. Clin Lung Cancer (2019) pmid: 30718102

Electronically signed by Jo-Anne Vergilio, M.D. | 19 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531